Dopaminagonists and fibrotic valvular heart disease: Further considerations

Authors

  • Olivier Rascol MD,

    1. Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France
    Search for more papers by this author
  • Atul Pathak MD,

    1. Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France
    Search for more papers by this author
  • Haleh Bagheri MD,

    1. Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France
    Search for more papers by this author
  • Jean-Louis Montastruc MD

    1. Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse, France
    Search for more papers by this author

Abstract

Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.

Ancillary